1. patients who are pregnant or breastfeeding. 2. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. 3. known sensitivity/allergy to hydroxychloroquine or favipiravir 4. current use of hydroxychloroquine for another indication 5. prior diagnosis of retinopathy 6. prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast\> 5 times the upper limit), hiv. 8. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 10. patient with irregular rhythm 11. patient with a history of heart attack (myocardial infarction) 12. patient with a family history of sudden death from heart attack before the age of 50 13. take other drugs that can cause prolonged qt interval 14. patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug 15. gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.

1. patients who are pregnant or breastfeeding. 2. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. 3. known sensitivity/allergy to hydroxychloroquine or favipiravir 4. current use of hydroxychloroquine for another indication 5. prior diagnosis of retinopathy 6. prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast\> 5 times the upper limit), hiv. 8. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 10. patient with irregular rhythm 11. patient with a history of heart attack (myocardial infarction) 12. patient with a family history of sudden death from heart attack before the age of 50 13. take other drugs that can cause prolonged qt interval 14. patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug 15. gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.

patients who are pregnant or breastfeeding. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. known sensitivity/allergy to hydroxychloroquine or favipiravir current use of hydroxychloroquine for another indication prior diagnosis of retinopathy prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. patient with irregular rhythm patient with a history of heart attack (myocardial infarction) patient with a family history of sudden death from heart attack before the age of 50 take other drugs that can cause prolonged qt interval patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.

patients who are pregnant or breastfeeding. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. known sensitivity/allergy to hydroxychloroquine or favipiravir current use of hydroxychloroquine for another indication prior diagnosis of retinopathy prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. patient with irregular rhythm patient with a history of heart attack (myocardial infarction) patient with a family history of sudden death from heart attack before the age of 50 take other drugs that can cause prolonged qt interval patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.

1. patients who are pregnant or breastfeeding. 2. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. 3. known sensitivity/allergy to hydroxychloroquine or favipiravir 4. current use of hydroxychloroquine for another indication 5. prior diagnosis of retinopathy 6. prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. 8. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 10. patient with irregular rhythm 11. patient with a history of heart attack (myocardial infarction) 12. patient with a family history of sudden death from heart attack before the age of 50 13. take other drugs that can cause prolonged qt interval 14. patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug 15. gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.

1. patients who are pregnant or breastfeeding. 2. will be transferred to a non-study site hospital or expected to be discharged within 72 hours. 3. known sensitivity/allergy to hydroxychloroquine or favipiravir 4. current use of hydroxychloroquine for another indication 5. prior diagnosis of retinopathy 6. prior diagnosis of glucose-6-phosphate dehydrogenase (g6pd) deficiency 7. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, iii. known history of ventricular arrhythmias, iv. current use of drugs that prolong the qt interval, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. 8. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 10. patient with irregular rhythm 11. patient with a history of heart attack (myocardial infarction) 12. patient with a family history of sudden death from heart attack before the age of 50 13. take other drugs that can cause prolonged qt interval 14. patient who is receiving immunosuppressive therapy (cyclosporin) which cannot be switched to another agent or adjusted while using the investigational drug 15. gout/history of gout or hyperuricemia (above the uln), hereditary xanthinuria or xanthine calculi of the urinary tract.